US Stock MarketDetailed Quotes
GDTC CytoMed Therapeutics
- 2.255
- +0.185+8.94%
Close May 15 16:00 ET
26.02MMarket Cap-8477P/E (TTM)
2.255High2.050Low711Volume2.050Open2.070Pre Close1.53KTurnover0.04%Turnover RatioLossP/E (Static)11.54MShares9.25052wk High3.11P/B3.81MFloat Cap1.92052wk Low--Dividend TTM1.69MShs Float9.250Historical High--Div YieldTTM9.90%Amplitude1.920Historical Low2.149Avg Price1Lot Size
CytoMed Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||
| Cash flow from continuing operating activities | -145.48%-3.43M | 18.36%-1.4M | -101.66%-1.71M | -849.44K |
| Net income from continuing operations | -32.04%-4.13M | -52.53%-3.13M | -6.01%-2.05M | ---1.94M |
| Operating gains losses | 2,075.11%252.51K | -95.75%11.61K | 31,046.55%273.26K | ---883 |
| Depreciation and amortization | -2.98%381.15K | 19.09%392.87K | 12.77%329.88K | --292.53K |
| Other non cash items | -290.48%-234.44K | 7.65%123.08K | 8.35%114.33K | --105.52K |
| Change In working capital | -4.53%104.92K | 129.76%109.9K | -419.44%-369.25K | --115.59K |
| -Change in receivables | 96.38%-5.26K | 66.48%-145.17K | -167.27%-433.12K | ---162.05K |
| -Change in payables and accrued expense | -56.81%110.18K | 299.37%255.07K | -77.00%63.87K | --277.64K |
| Cash from discontinued investing activities | ||||
| Operating cash flow | -145.48%-3.43M | 18.36%-1.4M | -101.66%-1.71M | ---849.44K |
| Investing cash flow | ||||
| Cash flow from continuing investing activities | -497.75%-2.83M | 42.54%-473.31K | -60.54%-823.67K | -513.05K |
| Net PPE purchase and sale | 87.68%-58.3K | 18.73%-473.31K | -137.96%-582.35K | ---244.73K |
| Net intangibles purchase and sale | ---- | ---- | ---- | ---20.43K |
| Net business purchase and sale | --0 | --0 | ---241.31K | --0 |
| Net investment purchase and sale | ---2.77M | --0 | --0 | ---247.9K |
| Cash from discontinued investing activities | ||||
| Investing cash flow | -497.75%-2.83M | 42.54%-473.31K | -60.54%-823.67K | ---513.05K |
| Financing cash flow | ||||
| Cash flow from continuing financing activities | 1,027.25%10.92M | -76.79%968.72K | 121.57%4.17M | 1.88M |
| Net issuance payments of debt | -164.39%-340.43K | -144.23%-128.76K | -80.45%291.09K | --1.49M |
| Net common stock issuance | 824.80%11.31M | -38.87%1.22M | 300.00%2M | --500K |
| Cash dividends paid | --0 | --0 | --0 | --0 |
| Net other financing activities | ---- | ---- | --2M | ---- |
| Cash from discontinued financing activities | ||||
| Financing cash flow | 1,027.25%10.92M | -76.79%968.72K | 121.57%4.17M | --1.88M |
| Net cash flow | ||||
| Beginning cash position | -37.13%1.58M | 183.84%2.51M | 138.66%885.27K | --370.94K |
| Current changes in cash | 615.82%4.66M | -155.17%-903K | 214.14%1.64M | --521.03K |
| Effect of exchange rate changes | 55.37%-13.41K | -224.92%-30.05K | -38.15%-9.25K | ---6.7K |
| End cash Position | 294.01%6.22M | -37.13%1.58M | 183.84%2.51M | --885.27K |
| Free cash flow | -86.47%-3.49M | 18.43%-1.87M | -105.93%-2.3M | ---1.11M |
| Currency Unit | SGD | SGD | SGD | SGD |
| Audit Opinions | Unqualified Opinion | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg